Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition
US11505607B2 · kind B2 · utility
1Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2022 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Jan 5, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16643
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition. The antibody named BiTEs-PD-L1 is a bispecific antibody capable of simultaneously binding CD3 and PD-L1 on the surfaces of tumor cells, and it can effectively activate T cells and guide T cells to kill tumor cells. The oncolytic virus oHSV2-BiTEs-PD-L1 is further developed by utilizing the BiTEs-PD-L1, it can reduce frequency and dosage of the administration. The present disclosure also confirmed several virus compositions with excellent antitumor effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.